Erik Buntinx

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

Lulu Bravo, Igor Smolenov, Htay Htay Han et al. · The Lancet · 2022 · 112 citations · Full text

Vaccinology, Vaccine Safety, Vaccination +9

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff et al. · The Lancet Infectious Diseases · 2022 · 84 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial

Heather Platt, Christopher Bruno, Erik Buntinx et al. · The Lancet Infectious Diseases · 2024 · 41 citations

Vaccination, Vaccine Safety, Vaccine Development +6

Evaluation of serotonin-2A receptor occupancy with 123I-5-I-R91150 and single-photon emission tomography before and after low-dose pipamperone administration in the canine brain

Kathelijne Peremans, Bart De Spiegeleer, Erik Buntinx et al. · Nuclear Medicine Communications · 2008 · 15 citations

Citalopram plus low-dose pipamperone <i>versus</i> citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response

Alan Wade, G. Crawford, Charles B. Nemeroff et al. · Psychological Medicine · 2011 · 15 citations